Bruker Corp. completed the acquisition of an 80% majority interest in Hain Lifescience GmbH.

Nehren, Germany-based Hain LifeScience offers molecular diagnostics solutions to detect microbial and viral pathogens and for molecular antibiotic resistance testing.

Under the Aug. 24 agreement, Bruker was granted the option to acquire the remaining 20% equity interest held by the German company's founders that can be exercisable in or after 2022.

Financial terms of the deal were not disclosed.

Billerica, Mass.-based Bruker, a manufacturer and distributor of scientific instruments, said the transaction will contribute 1 cent to 2 cents toward its 2019 non-GAAP earnings per share.